Vertex Pharmaceuticals (VRTX) , along with CRISPR Therapeutics (CRSP) , announced that the FDA expanded the label of their one-shot gene therapy Casgevy to treat transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older. The approval comes just a month after the FDA approved the therapy for sickle cell disease (SCD) in the same age group. Following this initial approval, Casgevy became the first gene therapy utilizing the Nobel prize- winning CRISPR technology. This technology can sel ...